n=701 screened

n=300 randomized

ASAQ  
n=150 allocated

AL  
n=150 allocated

n=150 exposed to treatment

n=150 exposed to treatment

Completed 42 days follow-up  n= 92 (61.3%)

Completed 42 days follow-up  n= 104 (69.3%)

Excluded  
n=401

< 2000 or > 200 000 Pf parasites /µl  356

No asexual Pf malaria (microscopy)  117

No informed consent  8

Signs of severe/complicated malaria  3

Presence of general danger signs  3

Severe malnutrition (WH<70%)  2

Concomitant febrile illness  2

n=1 excluded  (participated twice) a

n=701 screened

n=300 randomized

ASAQ  
n=150 allocated

AL  
n=150 allocated

n=150 exposed to treatment

n=150 exposed to treatment

n=149 mITT population

n=150 mITT population

n=142 PP population

n=126 PP population

Major protocol deviations  
n=7 (4.7%)

- Day0 Pf parasites < 2000 or > 200 000/µl  2 ***

- Any treatment dose missed, vomited not replaced, or delayed ≥ 1 calendar day  4

- ≥ 2 consecutive visits missed  1

Pre-mature discontinuations##  
n=3 (2.0%)

- Unable to complete follow up visits  1

- Withdrawal of consent  2

Major protocol deviations  
n=21 (14.0%)

- Any treatment dose missed, vomited not replaced, or delayed ≥ 1 calendar day  19 ###

- ≥ 2 consecutive visits missed  2

Excluded  
n=401

< 2000 or > 200 000 Pf parasites /µl  356

No asexual Pf malaria (microscopy)  117

No informed consent  8

Signs of severe/complicated malaria  3

Presence of general danger signs  3

Severe malnutrition (WH<70%)  2

Concomitant febrile illness  2